Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 20/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.66 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1725869 | 0.91 | ALOX5AP (0.75) | ALOX5APCYP3A4CYP2C9PTGS1CYP2D6 | |
| SCHEMBL176155 | 0.86 | ALOX5AP (0.84) | ALOX5APCYP3A4CYP2C9PTGS1CYP2D6 | |
| SCHEMBL15412581 | 0.86 | ALOX5AP (0.83) | ALOX5APPTGS1 | |
| SCHEMBL1723339 | 0.86 | ALOX5AP (0.85) | ALOX5APCYP3A4CYP2C9PTGS1 | |
| SCHEMBL170170 | 0.85 | ALOX5AP (1.00) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL15412583 | 0.85 | ALOX5AP (0.74) | ALOX5APCYP3A4CYP2C9PTGS1CYP2D6 | |
| SCHEMBL1723927 | 0.85 | ALOX5AP (0.89) | ALOX5APCYP3A4CYP2C9PTGS1ALOX5 | |
| SCHEMBL175975 | 0.84 | ALOX5AP (0.80) | ALOX5APCYP3A4CYP2C9PTGS1CYP2D6 | |
| SCHEMBL167607 | 0.84 | ALOX5AP (0.80) | ALOX5APCYP3A4CYP2C9PTGS1CYP2D6 | |
| SCHEMBL175527 | 0.84 | ALOX5AP (0.82) | ALOX5APCYP3A4CYP2C9PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710081-B2 | 5-lipoxygenase-activating protein (FLAP) inhibitors | PANMIRA PHARMACEUTICALS, LLC (US) | 2014-04-29 | — | — | US | disclosed |
| US-20140018394-A1 | 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AUTOIMMUNE PHARMA LLC | 2014-01-16 | — | — | US | disclosed |
| US-20110118315-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | AMIRA PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118315-A1 | 5-LIPOXYGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, ALOX15B, ALOX15 | ALOX5AP 4/4885CYP3A4 912/4885CYP2C9 2125/4885 |
| US-20140018394-A1 | 5-LIPOXGENASE-ACTIVATING PROTEIN (FLAP) INHIBITORS | ALOX5, LTA4H, ALOX5AP | ALOX5AP 3/4885CYP3A4 1258/4885CYP2C9 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.